于倩

作者: 时间:2024-04-30 点击数:

姓名

于倩

职称

主任药师,副教授,博士生导师


办公地点

BV伟德国际1946白求恩第三临床医学院药学部

办公电话

0431-84995215

邮箱

yuqian@jlu.edu.cn

教育背景

2013-2017 BV伟德国际1946 博士研究生 

2008-2011 BV伟德国际1946 硕士研究生 

1985-1989 长春医学高等专科学校 本科生

工作经历

2022-至今, BV伟德国际1946,白求恩第三临床医学院, 副教授/博士生导师

2013-至今, BV伟德国际1946,白求恩第三临床医学院, 主任药师/硕士生导师

2008-2013, BV伟德国际1946, 白求恩第三临床医学院, 主任药师 1996-2008, BV伟德国际1946, 白求恩第三临床医学院, 副主任药师 1990-1996, BV伟德国际1946, 白求恩第三临床医学院, 主管药师 1989-1990, BV伟德国际1946, 白求恩第三临床医学院, 药师

主讲课程

《药房管理》、《临床药学导论》、《新生研讨课》

研究领域

临床药学

科研成果

1.Wang Y,Yu Q,Tian Y,Ren S.,&Zhu,K.(2023).Unraveling the impact of nitric oxide, almitrine, and their combination in COVID-19 (at the edge of sepsis) patients: a systematic review.Front Pharmacol, 14:1172447 2.Jiang,Y.,Cui,H.,Yu,Q.(2024).A novel near-infrared fluorescent probe for high-sensitivity detection of butyrylcholinesterase in various pathological states.Spectrochim Acta A Mol Biomol Spectrosc, 308:123801 3.Yu,Q.,Lan,T.,Ma,Z.,Wang,Z.,&Zhao,Z.(2023).Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.Transl Androl Urol,12(8):1296-1307 4.Jiang,Y.,Jiang,Y.,Li,M.,Yu,Q.(2023).Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs? .Front Pharmacol,14:1143361 5.Jiang,Y.,Jiang,Y.,Ding,Z.,Yu,Q.(2022).Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability.Int J Nanomedicine,17:3443-3456 6.Lan,T.,Wang,H.,Li,X.,Yin,H.,&Yu,Q.(2022).The effect of clinical pharmacists' intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series.BMC Health Serv Res,22(1):925 7.Wang,Y.,Zhu,K.,Dai,R.,Li,R.,&Yu,Q.(2021).Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review.Front Pharmacol,12:804250 8.Lan,T.,Guan,L.,Pang,X.,Li,X.,&Yu,Q.(2022).Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.J Clin Pharm Ther,47(1):104-111 9.Jiang,Y.,Sui,D.,Li,M.,Xu,H.,&Yu,Q.(2021).Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice.Evid Based Complement Alternat Med,2021:9003603 10.Wang,Y.,Huo,P.,Dai,R.,Lv,X.,Yu,Q.,&Zhu K.(2021).Convalescent plasma may be a possible treatment for COVID-19: A systematic review. .Int Immunopharmacol,91:107262 11.Lan,T.,Zhang,X.,Yu,Q.(2020).Anaemia associated with Tacrolimus: A case report and literature review.J Clin Pharm Ther,45(6):1497-1500 12.Lan,T.,Yu,Q.(2020).Cistanches deserticola PhG-RE through Inhibiting ERS Apoptosis Mechanism to Protect Myocardial Cell Apoptosis from H2O2-Induced Endoplasmic Reticulum Stress. .Evid Based Complement Alternat Med,2020:8219296 13.李锐,谢程,郭义明 &于倩.(2020).临床试验用药品中心化管理中药师的价值与作用.中国临床药学杂志,29(06):436-439. 14.王战垒&于倩.(2020).洛铂在膀胱癌细胞中的抗肿瘤作用及通过PI3K/AKT信号通路促进凋亡的机制研究.中南药学, 18(01):20-24. 15.毕铁琳,李忻&于倩.(2019).注射用丹参多酚酸盐致新的不良反应1例.中国实验诊断学,23(11):2004-2005. 16.于倩,王华&谢程.(2019).基于真实世界的注射用丹参多酚酸临床用药合理性分析.药物评价研究,42(11):2238-2242. 17.张明淑 & 于倩 (2018) 医院药学概要. 人民卫生出版社. 18. 于倩,王华,李忻,严明兰,郭鑫,毕铁琳&郭义明.一种用于提高临床用药药品不良反应上报率的方法. 19.于倩, 谢程, 窦玉常, 刘宏宇, 李忻, 杨宗辉, 郭义明, 蒋倩 & 江一川.一种清胰的中药组合物及制剂工艺.

版权所有:中国·BV伟德国际体育官方网站 - 始于英国1946